Jazz
Jazz is intelligent automation software for neuroradiology from Swiss company AI Medical. It detects, annotates, quantifies and reports brain lesions on follow-up MRI, tracking each lesion across studies. FDA-cleared and CE-marked, it targets multiple sclerosis and brain metastasis reading.
What is Jazz?
Jazz is the flagship product of AI Medical AG, a Swiss research company based in Zollikon, on the edge of Zürich, which builds diagnostic software for neuroradiology. The tool addresses one narrow and laborious task: reading follow-up brain MRI, where a radiologist compares today's study against every previous one and decides which lesions are new, which have grown and which have resolved. In multiple sclerosis a single patient may present dozens or hundreds of lesions, and the comparison is traditionally done by hand.
Jazz combines lesion detection with workflow automation across what the vendor calls the entire neuroimaging lifecycle. Six capabilities are claimed: automation of low-level tasks, single-click annotation, automatic report generation, digitisation of findings, long-term quantification, and Swiss engineering quality. What ties them together is persistence — a lesion marked once is retained and re-identified in every subsequent study, so the next reader starts where the last one finished rather than beginning again. Volumes are measured in the patient's own anatomical space and presented as a dated series; a statistical view sorts lesions into stable, new, shrinking, expanding and resolved. The report arrives with numbered findings, each carrying a representative image.
Two case studies carry the evidence. Across Stanford University, University Hospital Zürich and Hôpital Poincaré in Paris, AI Medical reports 260% higher sensitivity for new multiple sclerosis lesions and 75% shorter reading time. In a clinical study supported by the Swiss innovation agency Innosuisse at University Hospital Zürich, covering 134 consecutive patients between September and November 2025, reading time fell by 98% in patients with no metastasis and by 93% in those with at least one. The company describes Jazz as FDA-cleared and CE-marked, and its footer carries CE 0297, ISO 13485 and MDSAP badges.
The scientific backing is substantial: nineteen peer-reviewed papers from 2020 to 2026 are listed. What the site withholds is equally telling — no price, no trial, no deployment mode, no named integration and no API. Everything technical is settled during a booked demonstration.
What it does
- Detect new lesions automatically on follow-up brain MRI
- Track slowly evolving lesions across successive studies
- Annotate a lesion once and reuse it in every later examination
- Quantify lesion volume in the patient's own anatomical space
- Generate a report with numbered findings, each carrying a representative image
- Show the distribution of lesion evolution: stable, new, shrinking, expanding, resolved
- Hand a reading over to the next reader without losing prior findings
When to use Jazz / When not to
A quick filter to help you decide if Jazz is the right fit.
When to use Jazz
- Neuroradiologists who read high volumes of follow-up brain MRI and need lesion changes surfaced automatically
- Multiple sclerosis specialists tracking dozens or hundreds of lesions across annual surveillance scans
- Neuro-oncology and radiosurgery teams following brain metastases through repeated treatment cycles
- Radiology departments where several readers succeed one another on the same patient and need continuity between readings
- Clinical research teams that need standardised volumetric endpoints across a longitudinal imaging dataset
When not to use Jazz
- Individual clinicians hoping to sign up and test the software alone: access runs exclusively through a booked demonstration
- Buyers who need a published price before opening a conversation, as no rate or range appears anywhere on the site
- Teams working outside brain MRI, since the tool addresses neuroradiology lesions and nothing else
- IT departments requiring documented PACS, DICOM or API integration before evaluation, none of which the vendor publishes
- Patients and non-clinicians, as this is a regulated medical device intended for imaging professionals
How to use Jazz
A typical end-to-end flow, from setup to results.
- Book a demonstration through the contact page or write to info@ai-medical.ch: there is no self-service sign-up
- Settle integration and deployment with the vendor, since the site publishes no technical prerequisite
- Open a follow-up brain MRI study in the Jazz interface
- Let the software detect candidate lesions and align the current study with the previous ones
- Mark a lesion once with a single click; Jazz retains it for every subsequent examination
- Review the volumetric measurements, expressed in the patient's own anatomical space
- Consult the statistical view to see which lesions are stable, new, shrinking, expanding or resolved
- Generate the report, which comes back with numbered findings and a representative image for each
- Hand the study on: the next reader picks up from the digitised findings instead of starting again
Pros & Cons
Pros
- Published gains are unusually specific: 260% higher sensitivity for new multiple sclerosis lesions and 75% shorter reading time across three independent centres
- A clinical study of 134 consecutive patients at University Hospital Zürich reports reading time cut by 98% and 93% on brain metastasis follow-up
- The vendor claims FDA clearance and CE marking, and displays CE 0297, ISO 13485 and MDSAP badges
- Nineteen peer-reviewed publications from 2020 to 2026 are listed, an uncommon level of scientific backing for a tool of this kind
- Named testimonials from identified neuroradiologists in Zürich, Toronto and New York, with institution and specialty stated
- Medical and strategic advisory boards are named, drawing on ETH Zürich, Stanford, Kyoto and Toronto
- The publisher is fully identifiable: complete imprint, postal address and Swiss company number CHE-416.568.892
Cons
- No price is published anywhere; the complete sitemap confirms the site carries no pricing page at all
- Neither a free trial nor a free plan is offered, so the only way in is a sales conversation
- No deployment mode is stated: nothing says whether Jazz runs in a browser, on a workstation or inside the PACS
- No integration is named, there is no API and no technical documentation is public
- The privacy policy covers the corporate website only and says nothing about the imaging data Jazz processes
- Imprint and privacy policy are JavaScript modals without URLs, so neither can be linked to nor archived by a third party
- The performance figures come from the vendor's own case studies rather than from independent evaluation
Pricing & Plans
No price is published. AI Medical maintains no pricing page — the complete sitemap, fourteen URLs, contains none — and no amount, currency or range appears anywhere on the site. Neither a free plan nor a free trial is announced. Access is arranged commercially: the only route is the Book a demo call to action or a message to the company's general address. Prospective buyers should expect a quotation drawn up institution by institution, as is customary for a regulated medical device sold to hospitals.
Data, GDPR & hosting
A consolidated view of how Jazz handles your data.
GDPR overview
Compliance is claimed in the footer of every page and detailed in a privacy policy last revised on 3 August 2026. AI Medical works under two regimes at once: the Swiss Federal Act on Data Protection, and the GDPR for visitors in the European Economic Area and the United Kingdom. Seven rights are enumerated — access and copy, rectification, erasure, restriction, portability, objection to legitimate-interest processing, and complaint to a supervisory authority — all exercised by writing to info@ai-medical.ch. The Swiss regulator is named: the Federal Data Protection and Information Commissioner, Feldeggweg 1, 3003 Bern. Transfers outside Switzerland and the EEA rest on EU Standard Contractual Clauses. No Article 27 representative and no data protection officer are designated. Two caveats: the policy addresses the website only, and it lives in a JavaScript modal with no URL, so it cannot be linked to or archived.
Who owns the data?
AI Medical AG, of Goldhaldenstrasse 22a in Zollikon, is named as the controller for the only data policy the company publishes, and that policy covers the corporate website alone. It states plainly that the site carries no user accounts, no login and no upload function, so it says nothing about who owns the imaging data, the annotations or the reports that Jazz produces in a clinical setting. For website data the company undertakes that it does not sell, rent or trade personal information, and processes it under the Swiss Federal Act on Data Protection together with the GDPR. Ownership terms at product level are simply not published and must be obtained from the vendor.
Reuse rights
The published policy governs website visits, not the product. It lists four purposes: delivering and securing the site, measuring aggregate traffic, answering enquiries including requests for a demonstration, and meeting legal obligations. Server logs record the IP address, timestamp, page requested, referrer and browser; aggregate statistics come from a cookieless analytics service that stores no identifier on the device and builds no cross-site profile. Correspondence is kept in order to answer the sender. The company states that it carries out no automated decision-making and no profiling. Nothing is said about whether a customer may reuse the data Jazz produces, nor about whether the vendor may reuse the images and annotations passing through it.
Data retention & training
Hosting summary
Only the corporate website's hosting is documented; nothing is published about where Jazz processes clinical images. The site runs on Vercel Inc., 440 N Barranca Ave #4133, Covina, California, acting as processor under a data processing agreement. Pages are served from Vercel's Frankfurt region, so server log data is processed within the European Union. Aggregate analytics may be handled by Vercel outside Switzerland and the EEA, including in the United States, under EU Standard Contractual Clauses; the company argues the risk is limited because those figures identify nobody. Incoming email passes through an unnamed mail provider. A DNS lookup on 31 August 2026 resolved the domain to 216.198.79.1, an anycast content-delivery node that geolocates to the United States and therefore says nothing about where the site is really served from. For a hospital evaluating Jazz the useful answer is missing: jurisdiction, residency and processing arrangements for patient imaging data are not stated and must be obtained from the vendor.
Things to keep in mind
Risks and trade-offs to weigh before adopting Jazz.
- The regulatory claim is asserted but not evidenced: no clearance number, certificate or indication scope is published, so the exact perimeter of the FDA and CE status has to be requested
- Every performance figure originates in the vendor's own case studies, published as first-party PDFs; none comes from independent evaluation
- Nothing is published about how Jazz handles patient data — hosting, retention, subprocessors, model training — because the privacy policy explicitly excludes the product from its scope
- No data processing agreement is offered, no data protection officer is named and no Article 27 representative is designated, all of which European hospital procurement will ask for
- Automation that hands the reader a pre-filled report invites automation bias: a finding the software does not surface can become a finding the reader stops looking for
- The legal pages are JavaScript modals with no URL, so the terms a buyer relies on today cannot be cited, archived or compared against a later version
- A wall of institution logos is not a client list; the site states no contractual relationship behind the names it displays
Setup & Integrations
Technical difficulty
Impossible to assess from the site, which describes no installation procedure, no technical prerequisite and no deployment mode. No PACS, DICOM or RIS integration is named and there is no API. Because access runs exclusively through a commercial demonstration, any rollout will be accompanied by the vendor rather than self-served. Day-to-day use is presented as straightforward — the interface is described as single-click — but ease of reading says nothing about ease of installation. Treat integration effort as an open question to settle during the demonstration.
Behind Jazz
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What exactly does Jazz do?
Who publishes Jazz?
Which conditions is it used for?
How much time does it actually save?
Is Jazz a certified medical device?
What does Jazz cost?
Is there a free trial?
Does Jazz offer an API or PACS integration?
What does the privacy policy cover?
Is there published evidence behind the product?
Should you pick Jazz?
Jazz is a narrow tool that does one difficult job and documents it seriously. Comparing today's brain MRI against years of previous studies is exactly the kind of repetitive, error-prone work that automation should absorb, and AI Medical backs its claims with figures, named clinicians and nineteen peer-reviewed papers — a level of evidence rare among AI imaging products. The regulatory posture is coherent too, with FDA clearance and CE marking claimed alongside ISO 13485 and MDSAP badges.
The reservations are about what is not said. Every performance figure comes from the vendor's own case studies rather than independent evaluation. No price, no trial and no deployment detail is published, so a buyer cannot judge fit, cost or integration effort before entering a sales conversation. Most consequentially for a hospital, the only published data policy covers the corporate website and explicitly excludes the product: nothing states where patient images are processed, how long they are kept, who the subprocessors are or whether they feed model training. No data processing agreement is offered and no data protection officer is named.
None of that is disqualifying — it is normal for a small medical device company selling through direct contact — but it moves the whole evaluation into the demonstration. Neuroradiology departments with heavy multiple sclerosis or brain metastasis follow-up volumes have a real reason to book that call. They should arrive with a written list: clearance number and indication scope, deployment architecture, PACS integration, data residency, retention, subprocessors, training policy, and a price. The product looks strong; the paperwork is the part that has to be requested.
- Choosing a selection results in a full page refresh.
- Opens in a new window.